Mostrar el registro sencillo del ítem

Efficacy of curcumin on prevention of drug-induced nephrotoxicity: A review of animal studies

dc.contributor.authorMotaharinia J.
dc.contributor.authorPanahi Y.
dc.contributor.authorBarreto G.E.
dc.contributor.authorBeiraghdar F.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:23:43Z
dc.date.available2020-09-02T22:23:43Z
dc.date.issued2019
dc.identifier10.1002/biof.1538
dc.identifier.citation45, 5, 690-702
dc.identifier.issn09516433
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5457
dc.descriptionDrug-induced nephrotoxicity is a frequent serious adverse effect, contributing to morbidity and increased healthcare utilization. Prevention or reversal is key. Curcumin has useful biological features that include antioxidant, anti-inflammatory, and anticancer properties. This review covers aspects of curcumin in relation to prevention of drug-induced nephrotoxicity: dosage and schedule, effect on kidney biomarkers and histological changes, and mechanisms of curcumin's protective effects. Despite success in some animal models, human studies and clinical administration of curcumin for nephroprotection remains limited due to difficulty in achieving therapeutic levels following oral administration and in determining the optimal dosing schedule. Lack of sufficient evidence from animal studies, coupled with low systemic bioavailability, continues to limit the utilization of curcumin in addressing and controlling drug-induced nephrotoxicity. Therefore, human studies are required to fully assess and validate the therapeutic potential of curcumin. © 2019 International Union of Biochemistry and Molecular Biology
dc.language.isoen
dc.publisherBlackwell Publishing Inc.
dc.subjectacute kidney injury
dc.subjectCurcuma longa
dc.subjectCurcumin
dc.subjectnephroprotection
dc.subjectnephrotoxicity
dc.subjectcreatinine
dc.subjectcurcumin
dc.subjectnitrogen
dc.subjecturea
dc.subjectantiinflammatory agent
dc.subjectantioxidant
dc.subjectcurcumin
dc.subjectmethotrexate
dc.subjectparacetamol
dc.subjectclinical assessment
dc.subjectclinical effectiveness
dc.subjectclinical trial (topic)
dc.subjectcreatinine blood level
dc.subjectdrug bioavailability
dc.subjectdrug efficacy
dc.subjectdrug exposure
dc.subjectdrug induced disease
dc.subjectdrug utilization
dc.subjecthistopathology
dc.subjecthuman
dc.subjectinflammation
dc.subjectkidney function
dc.subjectkidney injury
dc.subjectmethodology
dc.subjectnephrotoxicity
dc.subjectnonhuman
dc.subjectoptimal drug dose
dc.subjectoxidative stress
dc.subjectprimary prevention
dc.subjectpriority journal
dc.subjectregulatory mechanism
dc.subjectrenal protection
dc.subjectReview
dc.subjectrisk assessment
dc.subjecturea nitrogen blood level
dc.subjectacute kidney failure
dc.subjectanimal
dc.subjectbioavailability
dc.subjectchemistry
dc.subjectCurcuma
dc.subjectdrug administration
dc.subjectdrug effect
dc.subjectisolation and purification
dc.subjectkidney
dc.subjectkidney function test
dc.subjectmetabolism
dc.subjectoral drug administration
dc.subjectpathology
dc.subjectrat
dc.subjectAcetaminophen
dc.subjectAcute Kidney Injury
dc.subjectAdministration, Oral
dc.subjectAnimals
dc.subjectAnti-Inflammatory Agents
dc.subjectAntioxidants
dc.subjectBiological Availability
dc.subjectCurcuma
dc.subjectCurcumin
dc.subjectDrug Administration Schedule
dc.subjectHumans
dc.subjectKidney
dc.subjectKidney Function Tests
dc.subjectMethotrexate
dc.subjectRats
dc.titleEfficacy of curcumin on prevention of drug-induced nephrotoxicity: A review of animal studies
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85068178160.pdf
Tamaño:
3.877Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem